DSM announced that its proprietary XD Technology boosts bioreactor productivity and titers of mammalian cell culture processes by 5 - 10 fold for the production of proteins and antibodies. Recent studies completed at the R&D labs of DSM Biologics in Groningen, The Netherlands, demonstrated that the yields from CHO-based cell cultures can be increased 5 - 10 fold over their previous fed-batch processes using only off the shelf, commercially available media. The XD Technology has been tested for antibody and recombinant protein production across multiple cell lines, and the increase was realized in all cases.

Jaap Schilder, Site Director Groningen, comments, "This opens the door to a completely novel way of supplying drug substance for clinical trials and for market needs. The XD process increases the overall output of a facility dramatically and the process ­duration and handling is similar to any fed-batch process." DSM is currently working with multiple customers at the Groningen site for XD process ­development. They are booking development slots now for 2010.